Skip to main content

REVIEW article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1481950
This article is part of the Research Topic Elderly Patients and Lymphoma View all 3 articles

Cellular Therapy in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Provisionally accepted
Naseem Esteghamat Naseem Esteghamat 1*Aaron Tsumura Aaron Tsumura 1Gabriel Marquez-Arreguin Gabriel Marquez-Arreguin 2Joseph Tuscano Joseph Tuscano 1*
  • 1 Comprehensive Cancer Center, School of Medicine, University of California, Davis, Sacramento, California, United States
  • 2 School of Medicine, University of California, Davis, Sacramento, California, United States

The final, formatted version of the article will be published soon.

    Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically the curative-intent treatment for patients who demonstrated chemosensitivity to salvage therapy. However, a significant portion of patients do not make it autoHCT due to disease progression or overall fitness and eligibility. This is of particular concern in the older adult population. In recent years, significant advances in cellular therapies including chimeric antigen receptor (CAR) T-cells and bispecific antibodies, in addition to improvement in autoHCT tolerability, have allowed for additional treatment options for patients with R/R DLBCL. These novel therapies offer the potential for durable remissions and cure, and should be considered in older patients. We present a review focused on the safety and efficacy of cellular therapies in the older adult population with R/R DLBCL.

    Keywords: CAR T, CAR T cell, Elderly, DLBCL - Diffuse large B cell lymphoma, Autologous transplant (ASCT), Bispecific antibody (bsAb)

    Received: 16 Aug 2024; Accepted: 24 Sep 2024.

    Copyright: © 2024 Esteghamat, Tsumura, Marquez-Arreguin and Tuscano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Naseem Esteghamat, Comprehensive Cancer Center, School of Medicine, University of California, Davis, Sacramento, 95817, California, United States
    Joseph Tuscano, Comprehensive Cancer Center, School of Medicine, University of California, Davis, Sacramento, 95817, California, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.